NO932399L - Tiazolylvinylfenylderivater - Google Patents
TiazolylvinylfenylderivaterInfo
- Publication number
- NO932399L NO932399L NO932399A NO932399A NO932399L NO 932399 L NO932399 L NO 932399L NO 932399 A NO932399 A NO 932399A NO 932399 A NO932399 A NO 932399A NO 932399 L NO932399 L NO 932399L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- alkoxy
- hydroxy
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract 1
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 abstract 1
- 241000448747 Clasis Species 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010037423 Pulmonary oedema Diseases 0.000 abstract 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 208000005333 pulmonary edema Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/907,987 US5273986A (en) | 1992-07-02 | 1992-07-02 | Cycloalkylthiazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO932399D0 NO932399D0 (no) | 1993-07-01 |
| NO932399L true NO932399L (no) | 1994-01-03 |
Family
ID=25424972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO932399A NO932399L (no) | 1992-07-02 | 1993-07-01 | Tiazolylvinylfenylderivater |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US5273986A (fr) |
| EP (1) | EP0577003A1 (fr) |
| JP (1) | JPH0680654A (fr) |
| KR (1) | KR940005602A (fr) |
| CN (1) | CN1087086A (fr) |
| AU (1) | AU667107B2 (fr) |
| BR (1) | BR9302737A (fr) |
| CA (1) | CA2099295A1 (fr) |
| CZ (1) | CZ133493A3 (fr) |
| FI (1) | FI933037A (fr) |
| HU (1) | HUT72747A (fr) |
| IL (1) | IL106141A0 (fr) |
| MX (1) | MX9303958A (fr) |
| NO (1) | NO932399L (fr) |
| NZ (1) | NZ247988A (fr) |
| PL (1) | PL299544A1 (fr) |
| UY (1) | UY23609A1 (fr) |
| ZA (1) | ZA934603B (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830854A (en) * | 1992-12-14 | 1998-11-03 | Merck Sharp & Dohme, Limited | Method of treating cystic fibrosis using a tachykinin receptor antagonist |
| AU3522895A (en) * | 1994-09-13 | 1996-03-29 | F. Hoffmann-La Roche Ag | A process of making (e)-4-{3-{2-(4-cycloalkyl-2-thiazolyl) ethenyl}phenyl}amino-2 ,2-alkyldiyl-4-oxobutanoic acid anoic acid |
| RU2161612C2 (ru) * | 1994-10-14 | 2001-01-10 | Яманоути Фармасьютикал Ко., Лтд. | Производные азола, фармацевтическая композиция на их основе, промежуточные соединения |
| AU5347496A (en) * | 1995-04-21 | 1996-11-07 | Daiichi Pharmaceutical Co., Ltd. | Ethynylthiazole derivative |
| SE9804212D0 (sv) * | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| US7056917B2 (en) * | 2001-04-26 | 2006-06-06 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
| WO2002087589A1 (fr) * | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Medicament permettant d'inhiber une pompe d'elimination de medicament |
| SE0102299D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| EP2048137A1 (fr) * | 2004-02-18 | 2009-04-15 | AstraZeneca AB | Dérivés de la benzamide et leur utilisation comme activateurs de la glucokinase. |
| BRPI0507734A (pt) * | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| GB0423044D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| AU2005293343B2 (en) | 2004-10-16 | 2009-03-19 | Astrazeneca Ab | Process for making phenoxy benzamide compounds |
| GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| US20110059941A1 (en) * | 2005-05-24 | 2011-03-10 | Peter William Rodney Caulkett | 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| EP1902052B1 (fr) * | 2005-07-09 | 2012-11-28 | AstraZeneca AB | Dérivés d hétéroaryl benzamide utilisés en tant qu activateurs de la glk dans le traitement du diabète |
| EP2027113A1 (fr) * | 2005-07-09 | 2009-02-25 | AstraZeneca AB | Dérivés d'hétéroaryl benzamide utilisés en tant qu'activateurs de la glk dans le traitement du diabète |
| WO2007007040A1 (fr) * | 2005-07-09 | 2007-01-18 | Astrazeneca Ab | Composés 2-hétérocyclyloxybenzoyl amino hétérocyclyle en tant que modulateurs de glucokinase pour le traitement du diabète de type 2 |
| US9202182B2 (en) * | 2005-08-11 | 2015-12-01 | International Business Machines Corporation | Method and system for analyzing business architecture |
| TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| CL2007003061A1 (es) * | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
| BRPI0721143A2 (pt) * | 2006-12-21 | 2014-03-11 | Astrazeneca Ab | Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase |
| AU2009278929B2 (en) | 2008-08-04 | 2012-07-05 | Astrazeneca Ab | Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| WO2010116176A1 (fr) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Dérivé de pyrazolo [4, 5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité |
| AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
| CN102647984B (zh) | 2009-10-02 | 2015-03-25 | 埃维克辛公司 | 抗炎症的2-羰基噻唑和2-羰基恶唑 |
| CN105102438B (zh) | 2013-01-29 | 2019-04-30 | 埃维克辛公司 | 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物 |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| US20220324835A1 (en) * | 2018-01-26 | 2022-10-13 | Nurix Therapeutics, Inc. | Inhibitors of cbl-b and methods of use thereof |
| CN114364667A (zh) | 2019-04-09 | 2022-04-15 | 紐力克斯治疗公司 | 用于Cbl-b抑制的3-取代哌啶类化合物以及Cbl-b抑制剂与癌症疫苗和/或溶瘤病毒联合的用途 |
| JP2022532247A (ja) | 2019-05-17 | 2022-07-13 | ニューリックス セラピューティクス，インコーポレイテッド | Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用 |
| US12016860B2 (en) | 2021-04-08 | 2024-06-25 | Nurix Therapeutics, Inc. | Combination therapies with Cbl-b inhibitor compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62142168A (ja) * | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
| JPS63258854A (ja) * | 1987-04-16 | 1988-10-26 | Mitsubishi Kasei Corp | カルボキシスチレン誘導体およびそれを有効成分とする薬剤 |
| DE3723913A1 (de) * | 1987-07-18 | 1989-02-23 | Shell Agrar Gmbh & Co Kg | Neue phosphoniumsalze, ihre herstellung und verwendung |
| EP0318085A3 (fr) * | 1987-11-25 | 1990-03-14 | Merck Frosst Canada Inc. | Acides hétérazole-dialcanoiques |
| ES2052825T3 (es) * | 1988-07-15 | 1994-07-16 | Hoffmann La Roche | Derivados de cicloalquiltiazol. |
| US5001140A (en) * | 1989-04-17 | 1991-03-19 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| JPH02169583A (ja) * | 1988-12-22 | 1990-06-29 | Mitsubishi Kasei Corp | ビニルチアゾール誘導体およびそれを有効成分とする薬剤 |
| AU654140B2 (en) * | 1990-07-31 | 1994-10-27 | Lilly Industries Limited | N-benzyl indoles, processes for their preparation or pharmaceutical compositions containing them |
-
1992
- 1992-07-02 US US07/907,987 patent/US5273986A/en not_active Expired - Fee Related
-
1993
- 1993-06-24 EP EP93110073A patent/EP0577003A1/fr not_active Withdrawn
- 1993-06-25 ZA ZA934603A patent/ZA934603B/xx unknown
- 1993-06-25 NZ NZ247988A patent/NZ247988A/en unknown
- 1993-06-25 IL IL106141A patent/IL106141A0/xx unknown
- 1993-06-28 CA CA002099295A patent/CA2099295A1/fr not_active Abandoned
- 1993-06-28 HU HU9301881A patent/HUT72747A/hu unknown
- 1993-06-28 AU AU41562/93A patent/AU667107B2/en not_active Expired - Fee Related
- 1993-06-29 JP JP5185437A patent/JPH0680654A/ja active Pending
- 1993-06-30 UY UY23609A patent/UY23609A1/es unknown
- 1993-06-30 MX MX9303958A patent/MX9303958A/es unknown
- 1993-07-01 BR BR9302737A patent/BR9302737A/pt not_active Application Discontinuation
- 1993-07-01 CN CN93109528A patent/CN1087086A/zh active Pending
- 1993-07-01 CZ CZ931334A patent/CZ133493A3/cs unknown
- 1993-07-01 KR KR1019930012260A patent/KR940005602A/ko not_active Application Discontinuation
- 1993-07-01 NO NO932399A patent/NO932399L/no unknown
- 1993-07-01 FI FI933037A patent/FI933037A/fi not_active Application Discontinuation
- 1993-07-01 PL PL29954493A patent/PL299544A1/xx unknown
- 1993-09-02 US US08/116,386 patent/US5399702A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HUT72747A (en) | 1996-05-28 |
| EP0577003A1 (fr) | 1994-01-05 |
| UY23609A1 (es) | 1993-12-21 |
| MX9303958A (es) | 1994-04-29 |
| CN1087086A (zh) | 1994-05-25 |
| HU9301881D0 (en) | 1993-09-28 |
| US5399702A (en) | 1995-03-21 |
| JPH0680654A (ja) | 1994-03-22 |
| US5273986A (en) | 1993-12-28 |
| KR940005602A (ko) | 1994-03-21 |
| AU4156293A (en) | 1994-01-06 |
| BR9302737A (pt) | 1994-02-08 |
| IL106141A0 (en) | 1993-10-20 |
| ZA934603B (en) | 1994-01-05 |
| AU667107B2 (en) | 1996-03-07 |
| CA2099295A1 (fr) | 1994-01-03 |
| CZ133493A3 (en) | 1994-01-19 |
| PL299544A1 (en) | 1994-02-21 |
| NZ247988A (en) | 1995-11-27 |
| NO932399D0 (no) | 1993-07-01 |
| FI933037A0 (fi) | 1993-07-01 |
| FI933037A (fi) | 1994-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO932399L (no) | Tiazolylvinylfenylderivater | |
| ATE241601T1 (de) | Zwischenverbindungen zur herstellung von neunen pyridoncarbonsäurederivate oder deren salzen | |
| FI842935A0 (fi) | Tigogenin-cellubiosid foer att skoeta hyperkolesterolemia och arteriosklerosis. | |
| KR100257619B1 (en) | Azole compounds, their production and use | |
| HK1016177A1 (en) | New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency | |
| CA2318349A1 (fr) | Oestrone sulfamate inhibant l'oestrone sulfatase, compositions pharmaceutiques associees et methodes d'utilisation | |
| ES8707223A1 (es) | Un procedimiento para la preparacion de derivados de benzotiazol y benzotiofen. | |
| AU7578894A (en) | Methods for inhibiting smooth muscle cell proliferation and restinosis | |
| IE893294L (en) | Piperidinyl benzimidazoles | |
| DK0533504T3 (da) | Dihydropyridinderivater, der er nyttige ved antitumorterapi | |
| ATE31921T1 (de) | Amidine, verfahren zu ihrer herstellung und deren anwendung in der therapie. | |
| NZ333257A (en) | Substituted cyclohexyl-phenyl-glycolates as spasmolytic agents | |
| DK0783495T3 (da) | Quinoxalinderivater, der er egnede i terapi | |
| PL295932A1 (en) | Method of obtaining novel bezazepine compounds | |
| CA2246584A1 (fr) | Methode pour traiter la maladie de gilles de la tourette | |
| EP0215545A3 (fr) | Utilisation de composés benzamido-azabicyclo pour les traitements de la migraine, de la nausée, du vomissement et de l'arythmie cardiaque | |
| ES2159526T3 (es) | Nuevos derivados de 4-(3-benzofuranil)piperidinilo y 4-(3-benzotienil)piperidinilo y composiciones farmaceuticas que los contienen. | |
| WO1986007059A3 (fr) | Composes d'oxodiazine | |
| ES8203901A1 (es) | Un procedimiento para la preparacion de benzamidas. | |
| RU93048130A (ru) | Производные тиазолилвинилфенила | |
| GB2334032A (en) | Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents | |
| MY101991A (en) | Heterocyclic sulphonamides. | |
| ATE46156T1 (de) | 1,3-benzoxathiol-derivate, deren verwendung und deren herstellung. | |
| NZ332029A (en) | Sulfonamide substituted chromans, process for their preparation, their use as a medicament and pharmaceutical preparations comprising them | |
| IE831004L (en) | Long-acting theophylline in medicinal form |